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pts engrafted at a md of 22 (11-41) days. 6 pts lost complete
chimerism during follow up with proven relapse at a md of 401
days in four. At a md follow up of 23 (4-79) months probability of
overall (OS) vs eventfree survival (EFS) was 74% vs 50% for the
whole cohort. A trend towards better survival was seen in recipients
of related compared to unrelated transplants (100 vs 64 %, p0.06)
and in those with less advanced disease (90 vs 68 % in Dupriez 0 vs
12, p0.26). However the only signiﬁcant predictor for OS by
log rank test was the pretransplant CCI: 85 vs 34 % in pts with CCI
0 to 2 vs 3 to 6 (p0.01). Probability of EFS at day 480 was
signiﬁcantly less in pts with abnormal karyoptype compared to
those with no detectable anomalies (17 vs 61%, p0.01). Five pts
with decreasing chimerism received immunotherapy (3 DLI, 2
PBSC) with return to complete chimerism in three and postDLI
aplasia in one.- Conclusions: Our results support the use of
related and unrelated alloHCT as a curative treatment option in
MMM. Outcome is better in pts without disease associated and
disease independent comorbidity. For pts with abnormal karyotype
there is a considerable risk of relapse/reversal post transplant.
Especially in risk pts chimerism therefore should be monitored
closely as disease recurrence may respond to immunotherapy.
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UMBILICAL CORD BLOOD TRANSPLANTATION – REPORT OF 106 CASES
FROM A SINGLE BRAZILIAN INSTITUTION
Setubal, D.C.1, Medeiros, C.P.1, Bitencourt, M.A.1, Bonﬁm, C.M.1,
Funke, V.A.1, Zanis, J.1, Cesario, E.1, Carvalho, D.1, Nunes, E.1,
Oliveira, M.M.1, Pasquini, R.1 1BMT Center, Hospital de Clinicas da
Universidade Federal do Parana, Curitiba, Parana, Brazil.
Umbilical cord blood (UCB) has been used as a viable source of
hematopoietic stem cell for patients that need transplantation but
don’t have a suitable related donor. Between 1983 and December
2005, we performed 106 cord blood transplantations (CBT) in our
institution. Patients (pts) were treated for malignancies (n46),
Fanconi’s Anemia (FA) (n33) and other nonmalignant disorders
(n27). Median age was 6 (1-55) years. CB units were related in
14 and unrelated in 92 pts and HLA mismatch was 5/6 in 42 and
4/6 in 38 pts. Transplantation conditioning varied according to the
disease. Most pts received Cyclophosphamide with total body ir-
radiation or Bussulfan; 54 pts received antithymocyte globulin
(ATG) prior the transplantation. Graft versus host disease (GvHD)
prophylaxis consisted of Cyclosporine A (CsA)  methypred-
nisolone in 68 pts and CsA  Methotrexate in 25 pts. Median
nucleated and CD 34 cells were 6.85  107/Kg and 1.3  105/Kg
respectively. Engraftment was reached in 57% of pts. Acute GvHD
grade II-IV developed in 46% and extensive chronic GvHD in
18% of pts. The overall survival was 49% after median follow-up
of 2.1 years. Engraftment failure (28,3%) was the main cause of
death. In the Cox regression analysis ATG in the conditioning
regime (p0.002), HLA compatibility (p0.03) and infused nu-
cleated cell dose 3  10 7/Kg (p0.01) were independent pre-
dictors of neutrophil engraftment. Age  3 years (p0.01), bleed-
ing after transplantation (p0.001) and infection with identiﬁed
agent (p0.002) were signiﬁcantly associated with overall survival.
CD 34 cell count and viability, clonogenic capacity, original UCB
bank, cryopreservation time, malignant disease status and donor
type (related vs unrelated) were not associated with engraftment or
overall survival. These results conﬁrm that HLA compatibility and
the number of nucleated cells are signiﬁcantly associated with
neutrophil engraftment. We concluded that, despite a high en-
graftment failure observed, UCB is a feasible source for transplan-
tation.
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DEMONSTRATION OF A SINGLE MIHA SPECIFICITY RECOGNIZED BY
MEMORY CD8 T CELLS WHICH INDUCES RESISTANCE TO MHC-
MATCHED HEMATOPOIETIC ALLOGRAFTS
Shatry, A.M.1, Levy, R.B.1 1University of Miami, Miami, FL.
T cells that recognize transplantation antigens arise in sensitized
individuals following multiple blood transfusions or marrow trans-
plants as well as in multiparous females. Resistance to allogeneic
hematopoietic cell transplantation (HCT) in such sensitized indi-
viduals is consistent with the presence of a host memory T cell
(TM) population speciﬁc for donor cell antigens. We hypothesized
that a single donor minor histocompatibility (MiHA) epitope could
elicit antigen-speciﬁc CD8 TM capable of resisting MHC-
matched allogeneic hematopoietic cell engraftment. To address
this question, B6 mice were sensitized 2X to the H60 immuno-
dominant MiHA epitope utilizing marrow-derived dendritic cells
pulsed with the H60 (LTFNYRNL) peptide. Three weeks follow-
ing booster sensitization, circulating CD8 TM (CD44hi, Ly 6C)
were detected by tetramer staining. B6 (H2b) mice containing
CD8 H60 T cells were subsequently conditioned with 9.0 Gy
TBI and transplanted with 5 106 BALB.B (H2b) BM-TCD. One
week post-transplant, naive recipients of BALB.B (H60) or B6-
H60 congenic TCD-BM contained 10-fold higher levels of cir-
culating donor cells than the B6 dendritic cell/peptide sensitized
recipients. Donor progenitor cells were also signiﬁcantly reduced
in sensitized recipients of allogeneic TCD-BM at this time. In
contrast, two weeks post-HCT, recipients of syngeneic marrow
exhibited 10-fold greater frequency of circulating donor cells
compared to recipients of MHC-matched allogeneic marrow (
5% donor chimerism was detected). These ﬁndings demonstrate
that host T cells against a single donor MiHA determinant are
sufﬁcient to induce resistance to MHC-matched allogeneic mar-
row engraftment. These effector responses during HVG stand in
contrast to those by donor T cell responses post-HCT in which
single MiHA differences fail to induce GVHD. Finally, heterolo-
gous immunity to virus generates allo-reactive TM cells. Since
such TM repertoires could include speciﬁcity for MiHA immuno-
dominant epitopes, the presence of TM populations that can me-
diate resistance in ‘naı¨ve’ recipients may be more prevalent than
previously considered.
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SAFETY AND EFFICACY OF HIGH-DOSE BUSULFAN BY 90-HOUR CON-
TINUOUS INFUSION IN HEMATOLOGIC MALIGNANCY PATIENTS UN-
DERGOING ALLOGENEIC STEM CELL TRANSPLANTS
Shea, T.1, Walko, C.1, Serody, J.1, Gabriel, D.1, Comeau, T.1, Rao, K.1,
Ivanova, A.1, Sharf, A.1, Krasnov, C.1, Coghill, A.1, Whitley, J.1,
Lindley, C.1 1University of North Carolina at Chapel Hill, Chapel Hill,
NC.
Busulfan is used in allotransplantation for patients with hemato-
logic malignancies. IV busulfan has recently become available and
is widely used qd or qid x 4 with ﬂudarabine in both ablative and
reduced-intensity regimens. We have previously demonstrated the
beneﬁt of using a test-dose of IV busulfan to predict the systemic
exposure of this drug (Walko, ASCO, 2005) and report here on this
approach in pts receiving a 90 hr continuous infusion of full-dose
busulfan. Methods: All pts received a 0.8 mg/kg test dose admin-
istered over 2 hours and PK sampling at times 0, 2.5, 4, 5, and 6
hours. Pts began treatment with 30 mg/m2 ﬂudarabine qd x 5 and
either 0.8 mg/kg ABW IV busulfan (18 pts) or targeted busulfan to
achieve an AUC of 4800 (6 pts) or 5700 (5 pts) umole/min/hr/day
on days –7 to –3. PK sampling was done at hours 0, 12, 16, 18, 48,
60, 72, and 89.5. All pts received tacrolimus and 0 (9 pts), 1 (10 pts),
2 (8 pts) or 3 (2 pts) doses of 30 mg of IV alemtuzamab based on
disease and donor type for prevention of GVHD prior to initiation
of chemotherapy. The initial 18 pts were studied without dose
adjustments, followed by dose escalation with targeted systemic
exposure of the busulfan and dose adjustments as needed in the last
11 pts treated. Results: 29 pts (15 MRD, 14 MUD) ages 18-55
(median 40) with high-risk AML (15), ALL (5), CML (2), IMF (2),
MDS (2), or other diseases (3) were enrolled. All pts engrafted with
a median of 14 days to an ANC 500 and 7 days to a platelet count
 20K. No regimen-related deaths were observed in the ﬁrst 100
days post-transplant. Two patients had transient grade 3 hepatitis
and two had grade 3 mucositis. There have been no cases of VOD,
pulmonary ﬁbrosis, alveolar hemorrhage or CNS toxicity. One
death at day 190 from pneumonia and one at day 191 from hem-
orrhagic cystitis and enterococcal sepsis occurred for a non-relapse
mortality rate of 7%. 14 pts have developed grade 2, one grade 3
and one grade 4 aGVHD. 6 have extensive and 2 have limited
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cGVHD. 12 pts have relapsed at a median of 128 days (range
76-512) post transplant with a one year actuarial OS of 65%.
Conclusion: This approach permits accurate delivery of a targeted
systemic exposure to IV busulfan, is well-tolerated, and will allow
additional dose escalation. Relapse, as opposed to toxicity, remains
the major challenge.
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TREOSULFAN: AN ATTRACTIVE ALTERNATIVE IN THE CONDITIONING
IN BONE MARROW TRANSPLANT FOR THALASSEMIA
Smiers, F.J.1, Bredius, R.1, Ball, L.1, Lankester, A.1, Bakker, H.2,
Egeler, R.M.1 1Dept Pediatric Hemato Oncology and Bone Marrow
Transplantation, Leiden University Hospital, Leiden, Netherlands;
2Data Management Dept Pediatric Hemato Oncology and Bone Marrow
Transplantation, Leiden University Hospital, Leiden, Netherlands.
Traditionally Busulfan and Cyclofosfamide are used with or
without serotherapy in the conditioning for beta thalassemia. Due
to a high rejection rate in our institution, Melfalan has been added
resulting in a marked reduction of rejection. Toxicity of this reg-
imen is tolerable and consists mainly of mucositis and occasionally
of VOD.
Treosulfan is an alkylating agent with a supposedly lower toxicity
proﬁle than other alkylating agents.
In 12 previously treated thalassemia patients (class 2-3) condi-
tioned with Busulfan, Melfalan, Cyclofosfamide and serotherapy,
mucositis WHO grade 1-2 was seen in 2 patients and grade 3– 4 in
9 patients. VOD was seen in 4 patients and 2 patients had mild
VOD. One patient died due to MOF. Acute GVHD was seen in 6
patients. Chronic GVHD (mild) in 2 patients. Two patients re-
jected but were successfully retransplanted. Ten patients had full
donor chimerism, two patients showed stable mixed chimerism.
In comparison the results in 5 beta thalassemia patients (class 2-3)
conditioned with Treosulfan 10 -14 mg/m2, Cyclofosfamide 120
mg/kg, Melfalan 140 mg/m2 with additional serotherapy (either
ATG or Campath). Two patients had a matched unrelated donor,
3 patients had identical related donors. Three patients received
Treosulfan 10 mg/m2. One patient rejected early and was success-
fully retransplanted with Treosulfan 14 mg/m2. The remaining
two patients received Treosulfan 14 mg/m2. Engraftment was in
normal range. No acute or chronic GVHD was seen. Mucositis
was limited in 3 (WHO grade 2) and moderate to severe (WHO
grade 3-4) in 2 patients. No VOD was seen. Chimerism was stable
mixed in 2 and full donor in three.Conclusion: Treosulfan 14
mg/m2 is well tolerated in thalassemia bone marrow transplant
patients and shows a lower toxicity proﬁle than busulfan.
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IMPACTS OF COMORBIDITIES ON OUTCOMES OF PATIENTS (PTS)
YOUNGER THAN 60 YEARS OLD, DIAGNOSED WITH INDOLENT MALIG-
NANCIES AND TREATED WITH ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT): A MODEL FOR PTS WITH AUTOIMMUNE
DISEASES
Sorror, M.L.1, Storb, R.1,2, Storer, B.1,2, Maloney, D.G.1,2,
Sandmaier, B.M.1,2 1Fred Hutchinson Cancer Research Center; 2Uni-
versity of Washington, Seattle, WA.
The NIH has stated the growing need to explore the therapeutic
and curative potential of allogeneic HCT for autoimmune diseases
(BBMT 2005, 11:862). The safety of HCT in pts with signiﬁcant
comorbidities is of a concern. Here, we analyzed whether the
HCT-CI, a sensitive tool to capture comorbidities (Blood 2005,
106:2912), could assess how young (60 year old) pts with indolent
malignancies tolerated allogeneic HCT strategies as a hypothetical
model for pts with autoimmune diseases. A majority of pts received
myeloablative (MA) conditioning (n364) with cyclophosphamide
plus busulfan (79%) or 12 Gy TBI (21%), while a small group of
pts (n79) received nonmyeloablative (NMA)-conditioning with 2
Gy total body irradiation (18%) 90 mg/m2 of ﬂudarabine (82%).
Diagnoses were acute myeloid leukemia in 1st remission (27%),
chronic myeloid leukemia-chronic phase (40%), myelodysplasia-
refractory anemia (16%), chronic lymphocytic leukemia (8%), low
grade non-Hodgkin lymphoma (4%), and others (5%). At HCT,
NMA-pts differed from MA-pts with respect to age (median 52 vs
41 years,), prior high-dose HCT (9% vs 1%), unrelated grafts
(42% vs 31%), and G-PBMC as stem cell source (87% vs 49%).
HCT-CI scores of 1-2 and 3 were found among 33% and 35%
of NMA vs 35% and 17% of MA-pts, respectively. The most
frequent comorbidities were pulmonary (24%) and hepatic (16%).
After HCT, 4-year cumulative incidences of non-relapse mortality
(NRM) were 10%, 17%, and 36% for MA-pts with HCT-CI
scores of 0, 1-2, and 3, respectively. Proportional hazards mod-
els; adjusted for stem cell source, pt age, donor type, and diagnoses,
were used to estimate hazard ratios (HR) for NRM and survival.
MA-pts with HCT-CI scores of 1-2 or 3 had higher adjusted
HRs for NRM (1.85, p0.06 and 4.56, p0.0001) and all-cause
mortality (2.15, p0.003 and 4.59, p0.0001) compared to pts with
HCT-CI scores of 0. There were no statistically signiﬁcant differ-
ences in NRM between NMA and MA-pts with HCT-CI scores of
0, 1-2, or 3 ( p0.7, p0.1, p0.18, respectively); however, the
small numbers of pts receiving NMA conditioning in each stratum
limited the power of these comparisons. We conclude that among
young pts with indolent malignancies, NRM and survival are
strongly associated with comorbidity after MA-HCT. Therefore,
MA-HCT for treatment of autoimmune diseases might be contra-
indicated for pts with HCT-CI scores of 3. Additional data are
needed to clarify the usefulness of NMA-HCT in indolent dis-
eases.
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OUTCOME OF PATIENTS ACCORDING TO ETHNIC GROUPS RECEIVING
ALLOGENEIC STEM CELL TRANSPLANTATION IN MALAYSIA
Tan, S.M.1, Chang, K.M.1, Ong, T.C.2, Salleh, S.1, Sathar, J.1,
Purushothaman, V.1 1Hospital Kuala Lumpur, Kuala Lumpur,
Wilayah Persekutuan, Malaysia; 2Hospital Sultanah Aminah, Johor
Bahru, Johor, Malaysia.
A total of 106 patients received an allogeneic stem cell transplan-
tation at Kuala Lumpur Hospital between 5/1999 and 5/2006.
Majority received G-CSF stimulated bone marrow as stem cell
source while 20% received PBSC. The race distribution were 52%
Malays, 31% Chinese, 9% Indians and 9% other races. The me-
dian time to neutrophil engraftment was 19 days and platelet
engraftment was 18 days. There was no difference in engraftment
days of platelets and neutrophils between G-CSF stimulated mar-
row and PBSC. The overall survival OS was 61%, event-free
survival EFS was 54% and the 100-day transplant mortality rate
TRM was 16%. The cumulative relapse rate was 24% and the
graft-vs-host disease GVHD rate was 32%.
The overall survival rate according to race was 62% in Malays,
68% in Chinese and 50% in Indians. The cause for mortality in the
Malay race was GVHD at 52%, relapse 29% and infection 29%.
Amongst the Chinese, the major cause for mortality was relapse
60%, GVHD 20% and infection 10%. In the other races, the cause
of mortality was relapse in 70% and GVHD in 20%.
The incidence of moderate Grade II and severe Grade III-IV
acute GVHD was 40% and 29% in the Malays, 43% and 10% in
the Chinese and 22% and 22% in the Indians respectively. Simi-
larly the incidence of limited and extensive chronic GVHD was
12% and 34% in the Malays, 21% and 18% in the Chinese and 0%
and 38% in the Indians.
It is evident that the incidence of severe acute GVHD and
extensive chronic GVHD is higher in the Malays than the other
races. Severe GVHD was also the major cause of mortality
amongst the Malays than the other races. However the rate of
relapse was inversely lower in the Malays than in the Chinese and
Indians.
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ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN IMATINIB
ERA: A SINGLE CENTER COMPARATIVE ANALYSIS OF IMATINIB RE-
CEIVING PATIENTS TO IMATINIB NAIVE PATIENTS
Ugur Bilgin, A.1, Soydan, E.1, Topcuoglu, P.1, Arslan, O.1, Ozcan, M.1,
Gurman, G.1, Demirer, T.1, Akan, H.1, Beksac, M.1, Konuk, N.1,
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